ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery Centers

Key Takeaways

• ACCESS GPO partners with Medtronic for ASC distribution
• Affera system includes Sphere‑9 dual‑energy catheter
• PFA technology improves safety for atrial fibrillation ablation
• Physician‑led ASCs gain earlier access to advanced electrophysiology tools
• Agreement supports workflow efficiency and economic sustainability

Summary

ACCESS GPO has signed a multi‑year preferred agreement with Medtronic to supply the Affera™ Mapping and Ablation System, featuring the Sphere‑9™ catheter, to physician‑led ambulatory surgery centers across the United States. The partnership aims to accelerate adoption of pulsed field ablation (PFA) technology for atrial fibrillation by providing early access, workflow alignment, and economic support. Sphere‑9’s dual‑energy radiofrequency and PFA capabilities promise enhanced safety, efficacy, and procedural efficiency in the outpatient setting. The deal underscores a broader shift toward advanced cardiac electrophysiology care outside hospitals.

Pulse Analysis

Pulsed field ablation (PFA) has emerged as a disruptive technology in cardiac electrophysiology, offering rapid lesion creation with minimal thermal injury. As hospitals increasingly shift complex procedures to outpatient venues, the demand for scalable, safe, and efficient ablation platforms has surged. Ambulatory surgery centers (ASCs) are uniquely positioned to meet this demand, but they require equipment that aligns with high‑throughput workflows and stringent safety standards. The Affera™ system, paired with the Sphere‑9™ catheter, directly addresses these criteria, delivering both radiofrequency and PFA capabilities in a single, high‑density mapping tool.

The strategic agreement between ACCESS GPO and Medtronic leverages the physician‑led purchasing model to streamline procurement and financing for ASCs. By bundling the Affera system with dedicated implementation support, the partnership reduces capital barriers and accelerates clinical adoption. Physicians benefit from a unified platform that simplifies case preparation, shortens procedure times, and enhances lesion consistency, while ASC administrators gain predictable cost structures and improved procedural economics. This collaborative approach also reinforces physician governance, ensuring that clinical quality remains the primary driver of technology selection.

Industry analysts view this move as a bellwether for the broader migration of advanced cardiac care to outpatient settings. As more electrophysiology groups adopt PFA‑centric workflows, vendors will likely prioritize integrated solutions that combine mapping, ablation, and data analytics. The ACCESS‑Medtronic alliance not only expands patient access to state‑of‑the‑art therapy but also sets a template for future group‑purchasing agreements that balance innovation, cost containment, and clinical autonomy. In the coming years, the ripple effect could reshape reimbursement models and spur further investment in outpatient cardiac infrastructure.